Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Protein Biomarkers Detect Invasive Breast Cancer

By LabMedica International staff writers
Posted on 01 Oct 2014
The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated.

It has been estimated that 233,000 women will be diagnosed with breast cancer in the USA in 2014 and approximately 40,000 deaths occur from breast cancer each year. More...
While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.

Data is now available from a study that measured serum protein biomarkers (SPBs) known to be associated with breast cancer in over 163 serum samples from women with either breast cancer or benign breast conditions. In addition, 28 autoantibodies (AAbs) associated with cancer were analyzed in 31 of these patients. The study demonstrated that the addition of AAbs to a panel of SPBs greatly increases accuracy and using SPBs to distinguish benign from invasive breast cancer yields reasonable but non-clinically meaningful results in menopausal women.

Provista Diagnostics, Inc., (Scottsdale, AZ, USA) is a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, that announced the data highlighting Provista's proteomic diagnostic that measures multiple breast cancer-specific biomarker proteins in blood samples.

David Reese, PhD, president and CEO of Provista, said, “The presentation of this proof-of-concept data is a major milestone for Provista as we continue to advance the development of our robust pipeline to detect breast and gynecologic cancers in women. Accurate clinical diagnosis of breast cancer depends on the effective use of complementary technologies in conjunction with standard of care, such as imaging. We believe our proteomics approach, which combines the sensitivity of autoantibodies with the specificity of known serum protein biomarkers along with standard-of-care imaging, may reduce the number of missed actionable breast cancers while avoiding the stress and added diagnostic costs of false negative reports.” The study was presented at The American Society of Clinical Oncology's 2014 Breast Cancer Symposium (ASCO-Breast 2014) that took place from September 4-6, 2014, in San Francisco (CA, USA).

Related Links:
Provista Diagnostics


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.